The National Cancer Institute Renews Yale Cancer Center’s Designation
A Comprehensive Cancer Center for over 35 Years
For Immediate Release
Date: 9/12/07
Contact: Renee Gaudette 203-436-8533 or renee.gaudette@yale.edu
New Haven, Conn. – Yale Cancer Center’s designation as a comprehensive cancer center by the National Cancer Institute (NCI) was recently extended for an additional 5 years following an extensive grant submission and review process. The award includes $1.87 million in funding per year to support the Center’s research initiatives along with the continuation of the Center’s comprehensive status, the most prestigious level of designation from the NCI.
“Our tradition as an NCI designated comprehensive cancer center is continually strengthened by our successes in cancer treatment, research, and education. I am extremely grateful for the dedication and support of my colleagues at Yale Cancer Center, Yale School of Medicine, and Yale-New Haven Hospital for their immense contributions to the grant submission and I m pleased to lead such an outstanding group of cancer clinicians and scientists at Yale Cancer Center as we begin another 5 years of accomplishments with the sustained support of the National Cancer Institute,” said Richard L. Edelson, MD, Director of Yale Cancer Center.
Yale Cancer Center is one of 39 comprehensive cancer centers in the nation and the only one in Southern New England. Yale was one of the first 11 cancer centers to be designated comprehensive under the National Cancer Centers plan in 1974. The NCI designation is given to Centers who meet strict criteria for patient care, cancer research, clinical trials, and community outreach and education. Yale Cancer Center received an excellent evaluation from peer reviewers and the National Cancer Institute during its most recent grant submission.
The advantages of receiving care at a comprehensive cancer center for patients are numerous, including the large collection of oncologists specializing in specific types of cancer, many of whom are nationally known cancer physicians and leading researchers in their field. The close collaboration between research and clinical care also ensures patients receive the most innovative treatments available.
With over 230 members, Yale Cancer Center harnesses the scientific resources of Yale School of Medicine, Yale-New Haven Hospital, and Yale University and focuses on translational research, an approach through which laboratory discoveries are quickly and efficiently integrated with clinical patient care. For more information visit www.yalecancercenter.or